Schoenherr Thomas Edward sold $189K of TEM

Schoenherr Thomas Edward (CEO, Diagnostics) sold 2,694 shares of Tempus AI, Inc. (TEM) at $70.00 ($0.19M total) on 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schoenherr Thomas Edward
Published Aug 25, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The disclosed sale provides fresh, primary‑source information but its modest size limits market impact.

02

Market read

The filing is a routine insider transaction with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could offset any negative sentiment from the sale.

Relevance 3/10Novelty 4/10Timing: post‑filing disclosure

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Thomas Edward Schoenherr sold 2,694 shares of Tempus AI for $188,580 via a 10b5‑1 plan.

Expected impact

Possible modest downside pressure; price may dip 1‑2% on the news.

Evidence & confidence

The sale is relatively small for a mid‑cap biotech and executed under a pre‑arranged plan, limiting strong inference.

Market effects

Minimal impact on the broader biotech sector; similar insider sales are common.

None

Low

Counterpoint

The sale could be routine liquidity management; investors may view it as non‑material.

Key entities

  • Tempus AI, Inc.

    AI‑driven diagnostics company listed on Nasdaq under ticker TEM.

  • Thomas Edward Schoenherr

    CEO of Tempus AI, executing a 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.